An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.

ABSTRACT:

Context

Naltrexone hydrochloride treatment for alcohol dependence works for some individuals but not for everyone. Asn40Asp, a functional polymorphism of the mu-opioid receptor gene (OPRM1), might predict naltrexone response.

Objective

To evaluate whether individuals with alcoholism who are heterozygous (Asp40/Asn40) or homozygous (Asp40/Asp40) for the OPRM1 Asp40 allele respond better to naltrexone.

Design

Pharmacogenetic analysis conducted between January 1, 2001, and January 31, 2004.

Setting

Eleven academic sites in the COMBINE Study.

Participants

Recently abstinent volunteers who met all 3 of the following conditions: (1) DSM-IV criteria for primary alcohol dependence; (2) participation in the COMBINE Study; and (3) availability of DNA.

Intervent

SUBMITTER: Anton RF 

PROVIDER: S-EPMC2666924 | biostudies-literature | 2008 Feb

REPOSITORIES: biostudies-literature